Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what Americans are paying compared to other countries.

Orr Inbar, CEO and co-founder of QuantHealth, unpacks the growing frustration over drug prices and the misperceptions fueling distrust in the pharmaceutical industry. With clinical trials now more ...

Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...

The plan to steal the Mitchell Map from a sleepy small-town museum in Urbanna, Virginia, didn’t sound quite so ...

Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to ...

Untangling the sprawling, global supply chain will be complicated and expensive, and could inadvertently compete with other ...

ODMAP in Yakima County went live in March 2024, first with law enforcement agencies entering data through the Spillman record ...

The World Health Organization said on Thursday systemic weaknesses in the oversight of the global pharmaceutical supply chain ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

As the threat of counterfeiting continues to torment industry stakeholders and patients, more strategic approaches to ...

President Donald Trump has threatened tariffs on drugs coming from overseas, but it might take more than that to reroute the ...